CirCode Announces Feasibility Study Agreement to Explore the Potential of Circular RNA Therapeutics

Shanghai, China – CirCode Biomed announced today a feasibility study agreement with Bristol Myers Squibb to explore a potential therapeutic application of CirCode’s Circular RNA technology.   The collaboration aims to deepen current knowledge of how to translate circular RNA technology into potential drug candidates and will make use of CirCode’s proprietary circular RNA platform and Bristol Myers Squibb’s broad expertise in drug discovery.